CARDINALHEALTH ANTISEPTIC BZK TOWELETTES benzalkonium chloride swab United States - English - NLM (National Library of Medicine)

cardinalhealth antiseptic bzk towelettes benzalkonium chloride swab

cardinal health - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - benzalkonium chloride 0.133 g in 100 g

CARDINALHEALTH ANTIBACTERIAL BATHING WIPES- benzalkonium chloride liquid United States - English - NLM (National Library of Medicine)

cardinalhealth antibacterial bathing wipes- benzalkonium chloride liquid

cardinal health 200, inc. - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - benzalkonium chloride 0.12 g in 100 g - to decrease bacteria on skin.

CARDINALEXTRA STRENGTH ANTACID WINTERGREEN FLAVOR- calcium carbonate tablet, chewable United States - English - NLM (National Library of Medicine)

cardinalextra strength antacid wintergreen flavor- calcium carbonate tablet, chewable

cardinal health - calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb, carbonate ion - unii:7ujq5ope7d) - antacid relieves

HEALTHYLAX- polyethylene glycol 3350 powder, for solution United States - English - NLM (National Library of Medicine)

healthylax- polyethylene glycol 3350 powder, for solution

cardinal health - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - polyethylene glycol 3350 17 g in 17 g - laxative

CARDINAL EXTRA STRENGTH SMOOTH ANTACID ASSORTED FRUITS- calcium carbonate tablet, chewable United States - English - NLM (National Library of Medicine)

cardinal extra strength smooth antacid assorted fruits- calcium carbonate tablet, chewable

cardinal health - calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb) - antacid relieves:

KETOROLAC TROMETHAMINE injection, solution United States - English - NLM (National Library of Medicine)

ketorolac tromethamine injection, solution

cardinal health 107, llc - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings, precautions, dosage and administration, and adverse reactions ). patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days. (see also boxed warning ) ketorolac tromethamine is contraindicated in patients with previously demonstrated hypersensitivity to ketorolac tromethamine. ketorolac tromethamine is contraindicated in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. ketorolac tromethamine should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings – anaphylactoid reactions, and precautions – pre-existing asthma ). ketorolac tromethamine is contraindicated as prophylactic analgesic before any major surgery. ketorolac tromethamine is contraindicated in the setting of coronary artery bypass graft (cabg) surgery (see warnings ). ketorolac tromethamine is contraindicated in patients with advanced renal impairment or in patients at risk for renal failure due to volume depletion (see warnings for correction of volume depletion). ketorolac tromethamine is contraindicated in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine musculature, thus increasing the risk of uterine hemorrhage. ketorolac tromethamine inhibits platelet function and is, therefore, contraindicated in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis and those at high risk of bleeding (see warnings and precautions ). ketorolac tromethamine is contraindicated in patients currently receiving aspirin or nsaids because of the cumulative risks of inducing serious nsaid-related adverse events. the concomitant use of ketorolac tromethamine and probenecid is contraindicated. the concomitant use of ketorolac tromethamine and pentoxifylline is contraindicated. ketorolac tromethamine injection is contraindicated for neuraxial (epidural or intrathecal) administration due to its alcohol content.

KETOROLAC TROMETHAMINE injection, solution United States - English - NLM (National Library of Medicine)

ketorolac tromethamine injection, solution

cardinal health 107, llc - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). acute pain in adult patients ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings, precautions, dosage and administration, and  adverse reactions ). pat

IBUPROFEN tablet, film coated United States - English - NLM (National Library of Medicine)

ibuprofen tablet, film coated

cardinal health 107, llc - ibuprofen (unii: wk2xyi10qm) (ibuprofen - unii:wk2xyi10qm) - ibuprofen 400 mg - carefully consider the potential benefits and risks of ibuprofentablets and other treatment options before deciding to use ibuprofen.use the lowest effective dose for the shortest duration consistent withindividual patient treatment goals (see warnings ). ibu tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. ibu tablets are indicated for relief of mild to moderate pain. ibu tablets are also indicated for the treatment of primary dysmenorrhea. controlled clinical trials to establish the safety and effectiveness of ibu tablets in children have not been conducted. ibu tablets are contraindicated in patients with known hypersensitivityto ibuprofen. ibu tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin orother nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reactions, and precautions, preexisting asthm

PROMETHAZINE HYDROCHLORIDE- promethazine hydrochloride tablet United States - English - NLM (National Library of Medicine)

promethazine hydrochloride- promethazine hydrochloride tablet

cardinal health - promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - promethazine hydrochloride 25 mg - promethazine hydrochloride, is useful orally for: perennial and seasonal allergic rhinitis. vasomotor rhinitis. allergic conjunctivitis due to inhalant allergens and foods. mild, uncomplicated allergic skin manifestations of urticaria and angioedema. amelioration of allergic reactions to blood or plasma. dermographism. anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. preoperative, postoperative, or obstetric sedation. prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. therapy adjunctive to meperidine or other analgesics for control of post-operative pain. sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. active and prophylactic treatment of motion sickness. antiemetic therapy in postoperative patients. promethazine hydrochloride tablets, usp are contraindicated for use

PACERONE- amiodarone hydrochloride tablet United States - English - NLM (National Library of Medicine)

pacerone- amiodarone hydrochloride tablet

cardinal health - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone hydrochloride 200 mg - because of its life-threatening side effects and the substantial management difficulties associated with its use (see "warnings" below), pacerone® (amiodarone hcl) tablets are indicated only for the treatment of the following documented, life-threatening recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available antiarrhythmics or when alternative agents could not be tolerated. as is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of amiodarone hcl tablets favorably affects survival. pacerone® (amiodarone hcl) tablets should be used only by physicians familiar with and with access to (directly or through referral) the use of all available modalities for treating recurrent life-threatening ventricular arrhythmias, and who have access to appropriate monitoring facilities, including in-hospital and ambulatory continuous electrocardiographic monitoring and electrophysiologic techniques. because of the life-t